Moderna’s Norovirus Program Remains On Track Despite FDA Hold
The biotech disclosed that its norovirus vaccine program was under US FDA hold due to a case of Guillain-Barré syndrome, but said this would not affect timelines.
The biotech disclosed that its norovirus vaccine program was under US FDA hold due to a case of Guillain-Barré syndrome, but said this would not affect timelines.